Movatterモバイル変換


[0]ホーム

URL:


WEKO3

To
latlondistance
To

Field does not validate



インデックスリンク

アイテム

84d965cf-ef8e-41ac-97fd-260b9b992e75
名前 / ファイルライセンスアクション
Hema17_S32.pdf Hema17_S32.pdf (180.9 kB)
Item type学術雑誌論文 / Journal Article(1)
公開日2012-08-06
タイトル
タイトルAdult T cell Leukemia-Lymphoma
言語
言語eng
キーワード
主題SchemeOther
主題ATL
キーワード
主題SchemeOther
主題HTLV-1
キーワード
主題SchemeOther
主題Molecular pathophysiology
キーワード
主題SchemeOther
主題Prevention and treatment
資源タイプ
資源タイプ識別子http://purl.org/coar/resource_type/c_6501
資源タイプjournal article
著者 Tsukasaki, Kunihiro

× Tsukasaki, Kunihiro

Tsukasaki, Kunihiro

Search repository
抄録
内容記述タイプAbstract
内容記述Adult T-cell leukemialymphoma (ATL) was first described in 1977 as a distinct clinico-pathological entity with a suspected viral etiology. Subsequently, a novel RNA retrovirus, human T-cell leukemia/lymphotropic virus type 1 (HTLV-1) was isolated from a cell line established from the leukemic cells of an ATL patient, and the finding of a clear association with ATL led to its inclusion among human carcinogenic pathogens. The three major routes of HTLV-1 transmission are mother-to-child infections via breast milk, sexual intercourse, and blood transfusions. HTLV-1 infection early in life, presumably from breast feeding, is crucial in the development of ATL. The diversity in clinical features and prognosis of patients with this disease has led to its subtype-classification into four categories, acute, lymphoma, chronic, and smoldering types defined by organ involvement, and LDH and calcium values. In cases of acute, lymphoma, or unfavorable chronic subtypes (aggressive ATL), intensive chemotherapy such as VCAP-AMP-VECP is usually recommended. In cases of favorable chronic or smoldering ATL (indolent ATL), watchful waiting until disease progression has been recommended although the long term prognosis was inferior to those of, for instance, chronic lymphoid leukemia. Retrospective analysis suggested that the combination of interferon alpha and zidovudine was apparently promising for the treatment of ATL, especially for types with leukemic manifestation. Allogeneic hematopoietic stem cell transplantation is also promising for the treatment of aggressive ATL possibly reflecting graft vs. ATL effect. Several new agent-trials for ATL are ongoing and in preparation, including a defucosylated humanized anti-CC chemokine receptor 4 monoclonal antibody. Two steps should be considered for the prevention of HTLV-1-associated ATL. The first is the prevention of HTLV-1 infections and the second is the prevention of ATL among HTLV-1 carriers. So far, no agent has been found to be effective for the latter. Further investigation on the pathogenesis of ATL is crucial for the prevention and treatment of this refractory leukemialymphoma.
書誌情報 Hematology

巻 17, 号 SUPPL.1, p. S32-S35, 発行日 2012-04-01
出版者
出版者W. S. Maney & Son Ltd
ISSN
収録物識別子タイプISSN
収録物識別子10245332
DOI
関連タイプisVersionOf
識別子タイプDOI
関連識別子10.1179/102453312X13336169155330
権利
権利情報© W. S. Maney & Son Ltd 2012.
著者版フラグ
出版タイプAM
出版タイプResourcehttp://purl.org/coar/version/c_ab4af688f83e57aa
引用
内容記述タイプOther
内容記述Hematology, 17(SUPPL.1), pp.S32-S35; 2012
0
views
Views

Versions

Ver.12023-05-16 01:26:45.769528
Show All versions

エクスポート

OAI-PMH
  • OAI-PMHJPCOAR 2.0
  • OAI-PMHJPCOAR 1.0
  • OAI-PMHDublinCore
  • OAI-PMHDDI
Other Formats

Confirm


Powered byWEKO3


Powered byWEKO3


[8]ページ先頭

©2009-2025 Movatter.jp